Low-Dose Naltrexone Side Effects: Potentially Permanent Adverse Events Explained

Print or save as PDF

What side effects do LDN trials actually report?

LDN means naltrexone at doses far below the approved 50 mg tablet, typically 0.5 to 6 mg a day and most often 4.5 mg, used off-label and made mainly by compounding pharmacies [1]. A 2026 narrative review screened 105 studies, 15 of them randomized trials, and describes LDN as generally safe and well tolerated, with most studies using 4.5 mg daily; it also concludes that current evidence does not support routine clinical use [1]. The effects reported most often across LDN trials are insomnia, vivid dreams, nausea and dizziness [1].

Larger, better-controlled trials point the same way. A meta-analysis of four randomized fibromyalgia trials (222 patients) found a higher incidence of vivid dreams and nausea with LDN than placebo, but no significant difference in serious adverse events [3]. The 12-month INNOVA trial in 98 women with fibromyalgia reported adverse events in 68.8% of those on 4.5 mg and 72% of those on placebo, predominantly mild and transient, with no treatment-related serious events [4].

Smaller studies are consistent. In a crossover trial of 31 women with fibromyalgia, 4.5 mg naltrexone was rated equally tolerable as placebo and no serious side effects were reported [7]. In an 8-week pilot in 80 people with multiple sclerosis (60 completed), LDN was well tolerated, serious adverse events did not occur, and one participant withdrew for an adverse event unrelated to MS [8]. An earlier open-label Crohn's disease pilot of 17 patients named sleep disturbance as the most common side effect, occurring in seven [9].

The FDA labels describe the 50 mg tablet and the 380 mg monthly injection and give no guidance at LDN doses [2][6][1].

Can LDN cause permanent side effects?

The 12-month fibromyalgia trial reported predominantly mild, transient adverse events and no treatment-related serious events [4]. The trial followed participants for 12 months, so it cannot rule out rare effects or effects that appear later [4].

No low-dose naltrexone product is FDA-approved [1], and FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed [5]. The proposed mechanisms for LDN, TLR4 antagonism on microglia and brief opioid-receptor blockade with compensatory upregulation of endogenous opioid signaling, remain largely theoretical and speculative according to the 2026 review [1].

Precipitated opioid withdrawal: the documented serious harm

The tablet label lists as contraindications receiving opioid analgesics and being currently dependent on opioids, including being maintained on methadone or buprenorphine [2]. When an opioid antagonist is given to an opioid-dependent person, the tablet label says withdrawal symptoms usually appeared within five minutes of ingestion and lasted up to 48 hours, with mental status changes including confusion, drowsiness and visual hallucinations; fluid losses from vomiting and diarrhea have required intravenous fluids, and postmarketing cases have needed hospital admission and sometimes intensive care [2]. It has also happened in alcohol-dependent patients whose prescriber did not know about opioid use [2].

The label recommends a minimum of 7 to 10 opioid-free days for people previously dependent on short-acting opioids, and warns that patients switching from buprenorphine or methadone may be vulnerable to precipitated withdrawal for as long as two weeks [2]. The contraindication is written without any dose exception, and the labels give no LDN-specific guidance [2][1].

Does LDN harm the liver?

The naltrexone tablet label reports cases of hepatitis and clinically significant liver dysfunction during clinical development and after marketing, along with transient, asymptomatic transaminase elevations [2]. In placebo-controlled studies using up to 300 mg a day — five times the recommended dose — naltrexone caused hepatocellular injury in a substantial proportion of patients, and the label links this to dose [2]. In short-term alcohol-dependence trials, AST elevations occurred in 1.5% of people on oral naltrexone, 1.5% on Vivitrol and 0.9% on placebo [2][6]. The labels say to stop naltrexone for symptoms or signs of acute hepatitis [2][6].

The current naltrexone tablet label and the Vivitrol label carry no boxed warning [2][6]. The boxed warning in this drug family belongs to Contrave, a naltrexone-plus-bupropion weight-management product, and it is for suicidal thoughts and behaviors, not liver injury [10].

Mood, depression and suicidal thoughts

The tablet label states that depression, suicide, attempted suicide and suicidal ideation have been reported after marketing, that no causal relationship has been demonstrated, and that patients treated for alcohol or opioid dependence should be monitored [2]. In alcohol-treatment trials the rate ranges for new-onset depression were 0 to 15% on naltrexone versus 0 to 17% on placebo, and for suicide attempt or ideation 0 to 1% versus 0 to 3% [2].

Opioid pain relief during and after LDN

Patients taking naltrexone may not benefit from opioid-containing medicines, including cough and cold preparations, antidiarrheals and opioid analgesics [2]. In an emergency where opioid analgesia is needed during tablet therapy, the label says the amount of opioid required may be greater than usual and the resulting respiratory depression deeper and more prolonged [2]. The Vivitrol label suggests regional analgesia or non-opioid analgesics when opioid pain relief is needed during its blockade [6].

After naltrexone treatment ends, reduced opioid tolerance can make a previously tolerated opioid dose fatal [2][6]. The labels note this at the end of a dosing interval, after a missed dose, and after stopping treatment [2][6]. Both labels say to strongly consider prescribing or recommending an opioid overdose reversal agent such as naloxone or nalmefene [2][6]. The tablet label says naltrexone does not lead to physical or psychological dependence and that tolerance to its opioid-antagonist effect is not known to occur [2].

What is not known

Pregnancy data are thin: the tablet label is Pregnancy Category C, reports early fetal loss in rats and rabbits at high multiples of the human dose, and states there are no adequate and well-controlled studies in pregnant women [2]. The Vivitrol label says published case series are insufficient to identify a drug-associated risk [6]. The 2026 review notes that safety data for LDN in pregnancy and in liver or kidney impairment are sparse [1], and the tablet label states that interaction studies with non-opioid drugs have not been performed [2].